The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 344:1402-1403 May 3, 2001 Number 18
NextNext

Long-Term Outcomes after Treatment for Refractory Immune Thrombocytopenic Purpura

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: In April 1993, my colleagues and I reported in the Journal our experience with combination chemotherapy as a treatment for patients with severe refractory immune thrombocytopenic purpura.1 We now provide long-term follow-up data on the initial eight patients with immune thrombocytopenic purpura and on four additional patients (Table 1). All patients had severe disease with periodic mucosal bleeding, and in all splenectomy had failed, as had an average of five other therapies. Of the 12 patients treated, 5 had a complete remission (a normal platelet count) and 1 had a partial remission (a platelet count . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.